EMA Authorised: Capecitabine Medac (capecitabine) — medac Gesellschaft für klinische Spezialpräparate mbH

View source ↗

Summary

EMA authorised Capecitabine Medac for colorectal cancer. Medac Gesellschaft für klinische Spezialpräparate mbH is the marketing authorization holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Capecitabine Medac (capecitabine)

Snippet

Status: Authorised. Therapeutic area: Colorectal Neoplasms. MAH: medac Gesellschaft für klinische Spezialpräparate mbH. Decision date: 28/03/2025